Wearable nasal and respiratory technology company Rhinomed (ASX:RNO) has received an initial purchase order for one million Rhinoswabs from the Victorian Department of Health to support the state's testing capability.
The company this Victorian deal follows the recent NSW Health Pathology order of one million Rhinoswabs.
Rhinomed said its Rhinoswab technology improves the sample collection process. Is said the Rhinoswab is substantially more comfortable and easier to use than the standard nasal swab, captures a larger sample, can accelerate the sample collection process and significantly reduce queues and waiting times. Rhinoswab works with existing PCR pathology workflows and equipment and has equivalent cost and quality to the US and European standard of care nasopharyngeal swabs.
Rhinomed CEO Michael Johnson said, “We are pleased to receive further validation of the Rhinoswab from the Victorian Government. The Rhinoswab can make a meaningful impact on the SARS-CoV-2 testing process and enable more people to be tested quickly and easily. With well over 2 billion SARSCoV-2 tests having been carried out globally over the past 18 months (close to 26 million in Australia alone), there is a major opportunity for Rhinoswab to radically improve the testing process, clinical outcomes and user experience and we look forward to working with the Department of Health to deliver these outcomes.”
Rhinomed said it is continuing to scale up its manufacturing capabilities to accommodate growing domestic and international demand for its technology.